Overactive Bladder Therapeutics Pipeline Review, H1 2015 - 23 Companies & 32 Drug Profiles
M2 - Thu Jul 09, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gb7727/overactive) has announced the addition of the "Overactive Bladder - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Overactive Bladder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Overactive Bladder and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - Allergan, Inc. - Asahi Kasei Pharma Corp. - Astellas Pharma Inc. - Dong-A Socio Group - FemmePharma Global Healthcare, Inc. - Ferring International Center S.A. - Hydra Biosciences, Inc. - Ion Channel Innovations, LLC - Ipsen S.A. - Jeil Pharmaceutical Co., Ltd. - Laboratorios SALVAT S.A. - Lipella Pharmaceuticals, Inc. - Merck & Co., Inc. - Mezzion Pharma Co. Ltd. - MI.TO. Technology S.r.L. - NeuroSearch A/S - Recordati S.p.A. - Sanofi - Takeda Pharmaceutical Company Limited - TARIS BioMedical, Inc. - TheraVida, Inc. - Toray Industries, Inc. Drug Profiles - (mirabegron solifenacin succinate) - abobotulinumtoxin A - ADX-71441 - DA-8010 - FE-999309 - HC-067047 - JLP-1207 - mirabegron ER - NS-19504 - onabotulinumtoxin A liposomal - oxybutynin chloride - oxybutynin hydrochloride - Peptide to Antagonize PACAP Receptor for CNS and Overactive Bladder - pVAX-hSlo - REC-0438 - SAR-244181 - senrebotase - Small Molecule to Agonize GABAB Receptor for Overactive Bladder and Pain - Small Molecule to Antagonize Neurokinin-1 Receptor for Overactive Bladder - Small Molecules to Agonize Beta3-Adrenoceptor for Anxiety, Depression and Overactive Bladder - Small Molecules to Antagonize EP1 Receptor for Overactive Bladder - Small Molecules to Antagonize TRPM8 for Overactive Bladder and Pain - Small Molecules to Antagonize TRPV1 for Overactive Bladder - solifenacin succinate - solifenacin succinate - tacrolimus liposomal - tarafenacin - TD-302 - THVD-201 - THVD-202 - udenafil - vibegron For more information visit http://www.researchandmarkets.com/research/gb7727/overactive
AGN: 312.13 (+8.03), MRK: 57.95 (+0.57)